Is safe pharmacotherapy worthwhile?
Authors:
Kateřina Langmaierová 1,3; Jana Gregorová 2,3
Authors‘ workplace:
Oddělení klinické farmacie, Krajská zdravotní, a. s., Ústí nad Labem, pracoviště Teplice
1; Oddělení klinické farmacie, Nemocnice Na Bulovce, Praha
2; Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno
3
Published in:
Čas. Lék. čes. 2019; 158: 270-272
Category:
Review Article
Overview
The safety of pharmacotherapy can be monitored at different levels of the health system and the quality of health care provided can be assessed from different points of view. The Ministry of Health, the health insurance companies, the State Institute for Drug Control, the Institute of Health Information and Statistics, and the health care facilities themselves fulfill their roles. Safety is assessed differently at each level. Based on current knowledge, it follows that the monitoring of adverse effects is not only of safety but also of economic importance for health care facilities. At this point the proactive way of working of clinical pharmacist can play a major role specifically when they get involved in direct care of the patient.
Keywords:
clinical pharmacist – safety of pharmacotherapy – Adverse reactions
Sources
- Věstník MZ ČR 2012; 5.
- Ministerstvo zdravotnictví ČR. Resortní bezpečnostní cíle. MZ ČR, Praha, 2012.
- Zákon č. 372/2011 Sb., o zdravotních službách a podmínkách jejich poskytování.
- Vyhláška č. 102/2012 Sb., o hodnocení kvality a bezpečí lůžkové zdravotní péče.
- Prokeš M. Hodnocení kvality preskripce. Klinická farmakologie a farmacie 2008; 22: 118–122.
- Státní ústav pro kontrolu léčiv. www.sukl.cz
- Pokorná A, Štrombachová V, Mužík J et al. Národní portál Systém hlášení nežádoucích událostí. Ústav zdravotnických informací ČR, Praha, 2016.
- Gyllensten H, Rehnberg C, Jonssön AK et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open 2013, 3(6), e002574.
- Szkultecka-Debek M, Drozd M, Kiepurska N et al. An adverse events potential costs analysis based on Drug Programs in Poland. Dermatology focus. Curr Issues Pharm Med Sci 2014; 27: 183–186.
- Lagnaoui RN, Moore J, Fach M et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 56: 181–186.
- Giardina C, Cutroneo PM, Moccario E et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front Pharmacol 2018; 9: 350.
- Mladá, J. Nežádoucí účinky léčivých přípravků – proč se jimi zabývat? Urologie pro praxi 2010; 11: 108–109.
- Gregorová J et al. Význam klinickofarmaceutické péče. In: Gregorová J, Langmaierová K. Klinickofarmaceutická péče v České republice: Popis aktuálního stavu a stanovení cílů. Maxdorf, Praha, 2019: 31–34.
- Rychlíčková J, Šaloun J, Gregorová J. Evaluation of clinical pharmacists' interventions in the Czech Republic. Pharmacotherapy 2016; 36: 766–773.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Medication treatment of singultus in palliative care
- Intrapleural alteplase therapy: what are the knowns and unknowns?
- Sleep and its disturbances in neurology
- Proton pump inhibitors from clinical pharmacist’s point of view